Anthem Biosciences Shares Make Robust Debut, List With 27% Premium On NSE

Anthem Biosciences Listing: Anthem Biosciences Ltd shares listed on the bourses on July 21 with robust gains. Anthem Biosciences shares listed on the NSE and BSE at Rs 723.05 apiece and Rs 723.1 apiece respectively. Shares of the pharmaceutical company listed with a premium of 26.85 per cent compared to the upper end of the public issue’s price band of Rs 570 apiece. The stock soon surged 31 per cent to trade at an early high of Rs 747 apiece.

Retail investors who were allotted at least one lot or 26 shares would have made a minimum profit of  Rs 3,979.3 (Rs 723.05- Rs 570 x 26) after the stock started trading on the exchange. After the stock began to trade, 208.14 lakh shares of the company changed hands on the NSE. The company's total market capitalization stood at Rs 40,997.53 crore.

Anthem Biosciences IPO: Details

Anthem Biosciences Ltd raised Rs 3,395.79 crore through its public issue, the issue consisted completely of an offer-for-sale of 5.96 crore shares. Anthem Biosciences IPO price band was set between Rs 540 to Rs 570 per share per share.  

The minimum lot size for application for retail investors was fixed at 1 lot consisting of 26 shares, which aggregated to an investment of Rs 14,040. Anthem Biosciences IPO was booked 63.86 times during the three-day bidding window which opened on July 14 and closed on July 16. Investors across categories placed bids for over 2,81,45,24,128 shares compared to the 4,40,70,682 shares offered for subscription.

The non-institutional investors (NII) quota of Anthem Biosciences IPO was booked 42.36 times. The Anthem Biosciences IPO was booked 5.64 times in the retail individual investor category. The mainboard issue was booked 182.65 times in the Qualified Institutional Buyers (QIB) category. Anthem Biosciences IPO was booked 6.6 times in the employee's category.

Anthem Biosciences mentioned in its Red Herring Prospectus that the company will not get any proceeds from the public issue. The proceeds of the public issue will go to the selling promoters Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj.

Anthem Biosciences Ltd started its operations in 2006. The company operates as a Contract Research, Development, and Manufacturing Organisation (CRDMO) within the pharmaceutical industry in India. The company has fully integrated operations ranging from drug discovery, development, and other manufacturing processes. Anthem Biosciences Ltd clientele includes customers ranging from emerging biotech firms to large pharmaceutical companies. The products made by the company include fermentation-based Active Pharmaceutical Ingredient (APIs), probiotics, enzymes and other pharmaceutical goods.

At the time of writing shares of Anthem Biosciences shares traded at Rs 730.05 apiece up by 0.97 per cent on the NSE.